Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof
US-9822181-B2 · Nov 21, 2017 · US
Heterodimeric antibodies that bind somatostatin receptor 2
US12054545B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12054545-B2 |
| Application number | US-202117542341-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 3, 2021 |
| Priority date | Jun 28, 2016 |
| Publication date | Aug 6, 2024 |
| Grant date | Aug 6, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind somatostatin receptor 2 (SSTR2).
First claim
Opening claim text (preview).
What is claimed is: 1. A somatostatin receptor type 2 (SSTR2) antigen binding domain comprising a variable heavy domain having at least 90% identity to the amino acid sequence of SEQ ID NO:958, and a variable light domain having at least 90% identity to the amino acid sequence of SEQ ID NO:962. 2. A SSTR2 antigen binding domain according to claim 1 wherein said variable heavy domain has the amino acid sequence of SEQ ID NO:958, and said variable light domain has the amino acid sequence of SEQ ID NO:962. 3. A nucleic acid composition comprising: a) a first nucleic acid encoding the variable heavy domain of claim 1 or 2 ; and b) a second nucleic acid encoding the variable light domain of claim 1 or 2 . 4. An expression vector composition comprising: a) a first expression vector comprising the first nucleic acid of claim 3 ; and b) a second expression vector comprising the second nucleic acid of claim 3 . 5. A host cell comprising the nucleic acid composition of claim 3 or the expression vector composition of claim 4 . 6. A method of making a SSTR2 binding domain comprising culturing the host cell of claim 5 under conditions wherein the SSTR2 binding domain is expressed, and recovering the SSTR2 binding domain.
Assignees
Inventors
Classifications
variable (Fv) region, i.e. VH and/or VL · CPC title
Hinge · CPC title
Constant or Fc region; Isotype · CPC title
Antineoplastic agents · CPC title
Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12054545B2 cover?
- The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind somatostatin receptor 2 (SSTR2).
- Who is the assignee on this patent?
- Xencor Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2809. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).